trending Market Intelligence /marketintelligence/en/news-insights/trending/FS-lQ54skTeGbq5fc_ylmA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Health Discovery terminates agreement, pursues legal action against NeoGenomics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Health Discovery terminates agreement, pursues legal action against NeoGenomics

Health Discovery Corp. said it was terminating a license agreement with Neogenomics Inc. as a result of a "material breach."

The 2012 license provided for the use of Health Discovery's technology to formulate and commercialize laboratory tests that could diagnose certain types of cancers.

NeoGenomics had paid $1 million in cash and issued 1,360,000 of its shares in upfront payment for the license.

Health Discovery said that NeoGenomics "failed to use best efforts" during the development term of the agreement and did not provide usage report of the technology despite repeated requests.

NeoGenomics is now barred from using the technology or any product and service developed as a result of said technology. Health Discovery said it would pursue legal action against the company and is evaluating potential damages given NeoGenomics' failure to perform its obligations as part of the agreement.